ACE2 and COVID-19: Interestingly, a recent study revealed that MSCs fail to express the receptor for angiotensin-converting enzyme 2 (ACE2) and, thus, should be insusceptible to SARS-CoV-2 infection.11 Therefore, we posit that MSCs could substantially improve the outcomes of COVID-19 patients by modulating the immune response, decreasing the extent of lung-tissue injury and facilitating its repair, and eventually, relieving acute pulmonary edema.